ZTS · Zoetis Inc
Price
Snapshot
50 fields · last close| Market Cap | $31.87B |
| P/E | 12.03 |
| Float | 418.6M |
| Beta | 0.69 |
| Volatility | 17.3% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 70 |
| Price | 75.42 |
| Change | −1.14% |
| Prev Close | 76.29 |
| Open | 77.01 |
| Day Low | 74.74 |
| Day High | 78.00 |
| Avg Vol | 4 |
| Avg $ Vol | $339.3M |
| 52W High | 155.15 |
| 52W Low | 71.00 |
| 52W Pos | 5.3% |
| From High | −51.39% |
| From Low | +6.23% |
| Max DD 1Y | −53.13% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −0.34% |
| SMA 50 | −0.26% |
| SMA 200 | −26.96% |
| RSI (14) | 50.3 |
| Vol 30D | 37.5% |
| Vol 90D | 53.2% |
| 1Y Range | 71–155 |
| Daily bars | 506 |
| Perf Week | +1.69% |
| Perf Month | +2.55% |
| Perf Quarter | −4.06% |
| Perf Half Y | −37.58% |
| Perf Year | −49.95% |
| Perf YTD | −40.10% |
| Prev Day | −1.14% |
| Clavix | B |
| Debt / Eq | 2.72 |
| Curr Ratio | 3.03 |
| Int Cover | 12.7× |
| FCF Margin | 26.6% |
| Rev Growth | +0.3% |
| Profit | Profitable |
| Leverage | High |
| Sector rank | 11 / 15 |
What ZTS does
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.
It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.
In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health.
It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health.
Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Clavix risk grade
regraded every trading dayZTS grades B, 70 of 100. Steadiest on News Sentiment (69), most exposed on Price Stability (50, mixed). 1 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 11 of 15 in Pharmaceuticals by Clavix score.
How rough the ride is
| ZTS | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.69 | 0.43 |
| Volatilityannualized | 17.3% | 10.7% |
| Max drawdown, past yearworst peak-to-trough fall | −53.1% | — |
| Typical daily movemedian absolute daily change | 0.93% | — |
| Days beyond ±3%of the last 252 sessions | 2510% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ZTS | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.69 | 0.43 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ZTS | |
|---|---|
| 1 week | +1.7% |
| 1 month | +2.6% |
| Year to date | −40.1% |
| 1 year | −50.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ZTS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 6 Aug |
| Average score0 most bearish, 100 most bullish | 44 |
| Bullish · bearisharticles above 60 · below 40 | 8 · 14 |
| Directionarticles whose tone is improving vs worsening | 8 ↑ 14 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| ZTS | |
|---|---|
| Revenue growthyear over year | +0.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Pharmaceuticals
15 companies| Metric | ZTS | Sector spread | Median |
|---|---|---|---|
| Beta | 0.69 | 0.43 | |
| Volatility | 17.3% | 10.7% | |
| Debt / equity | 2.72 | 0.94 | |
| Current ratio | 3.03 | 1.86 | |
| FCF margin | 26.6% | 20.8% | |
| Interest coverage | 12.7× | 5.9× |
Recent news
most recent scored articles · the chip is the article’s score · click to openZoetis reported flat fiscal Q2 2026 revenue of $2.5 billion, down 1% on an organic operational basis, with weakness in the U.S. companion-animal market pressuring results despite the company's strong overall position in animal health. The article questions whether Zoetis's product pipeline can return the business to growth.
Stifel Nicolaus lowered its price target on Zoetis from $85 to $80 and set a 'hold' rating on the stock in a report issued Thursday.
Zoetis received FDA Emergency Use Authorization for its Simparica Trio chewable to treat New World screwworm infestations in dogs, appointed Jay Saccaro as its new Chief Financial Officer and Chief Operating Officer, and lowered its full-year 2026 revenue and earnings guidance to reflect a more cautious outlook.
Zoetis is scaling AI across its $10 billion business through a program called AI@Zoetis, led by chief digital and technology officer Keith Sarbaugh. The company built a generative AI platform that now reaches about 95% of employees, giving them access to 10 large language models and resulting in more than 11,000 employee-built AI agents used in areas like research, manufacturing, customer experience, and career development.
Zoetis is going through the steepest stock decline in its history as U.S. veterinary clinic visits fall and competition ramps up across its companion animal franchises (pet-focused product lines like vaccines and parasite treatments).
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| RPRX | Royalty Pharma PLC | A | $36.73B | 45.07 | 0.38 | Compare |
| VTRS | Viatris Inc | B+ | $20.71B | — | 0.91 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $16.07B | 17.04 | 0.38 | Compare |
| ELAN | Elanco Animal Health Inc | B- | $12.20B | — | 1.75 | Compare |
| CORT | Corcept Therapeutics Inc | C- | $12.19B | 216.52 | 0.50 | Compare |
| AXSM | Axsome Therapeutics Inc | B | $10.91B | — | 0.81 | Compare |
| CRNX | Crinetics Pharmaceuticals Inc | D+ | $9.01B | — | 0.45 | Compare |
| BMY | Bristol-Myers Squibb Co | B+ | $139.1B | 14.87 | 0.19 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.